IRVINE, Calif.--(BUSINESS WIRE)--
Aerie Pharmaceuticals, Inc. (Nasdaq:AERI), a clinical-stage
pharmaceutical company focused on the discovery, development and
commercialization of first-in-class therapies for the treatment of
glaucoma and other diseases of the eye, today announced that Vicente
Anido, Jr., Ph.D., Chairman and Chief Executive Officer, will present at
the Canaccord Genuity Growth Conference on Wednesday, August 9, 2017 at
3:30 p.m. Eastern Time in Boston, MA.Dr. Anido will provide an Aerie
overview and business update.
The presentation will be webcast live and may be accessed by visiting
Aerie's website at http://investors.aeriepharma.com/.
A replay of the webcast will be available for 10 business days.
About Aerie Pharmaceuticals, Inc.
Aerie is a clinical-stage pharmaceutical company focused on the
discovery, development and commercialization of first-in-class therapies
for the treatment of patients with glaucoma and other diseases of the
eye. Aerie's two current product candidates are once-daily intraocular
pressure lowering therapies with novel mechanisms of action to treat
patients with glaucoma or ocular hypertension. The NDA (new drug
application) for Rhopressa™ (netarsudil ophthalmic solution) 0.02% was
submitted to the U.S. Food and Drug Administration (FDA) in February
2017, and, in May 2017, the FDA set the PDUFA (Prescription Drug User
Fee Act) goal date for the completion of the FDA's review of the
Rhopressa™ NDA for February 28, 2018. Aerie's second product candidate,
Roclatan™ (netarsudil/latanoprost ophthalmic solution) 0.02%/0.005%,
which is a fixed dose combination of Rhopressa™ and widely prescribed
PGA latanoprost, achieved its primary efficacy endpoint in two Phase 3
registration trials, named Mercury 1 and Mercury 2, and also achieved
successful 12-month safety and efficacy results in Mercury 1. The
Roclatan™ NDA submission is expected to take place in the first half of
2018. Aerie is also focused on the development of additional product
candidates and technologies in ophthalmology.
View source version on businesswire.com: http://www.businesswire.com/news/home/20170802005025/en/
Richard Rubino, 908-947-3540
McClellan, Inc., on behalf of Aerie Pharmaceuticals
Source: Aerie Pharmaceuticals, Inc.
News Provided by Acquire Media